Table 4 Toxicity for the different polymorphisms, according to treatment received (chemotherapy or chemotherapy with platinum).
Variable | Chemotherapy toxicity | Chemotherapy with platinum toxicity | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Cases, n (%) | Controls, n (%) | Crude OR (95% CI) | p-value | Adjusted ORa (95% CI) | p-value | Cases, n (%) | Controls, n(%) | Crude OR (95% CI) | p-value | Adjusted ORa (95% CI) | p-value | |
GSTM1 | ||||||||||||
Salvage gene/heterozygous | 10 (50) | 11 (40.7) | 1 (–) | 1 (–) | 8 (47.1) | 9 (39.1) | 1 (–) | 1 (–) | ||||
Homozygous | 10 (50) | 16 (59.3) | 0.69 (0.21–2.21) | 0.53 | 0.51 (0.12–2.19) | 0.37 | 9 (52.9) | 14 (60.9) | 0.72 (0.2–2.59) | 0.62 | 0.46 (0.08–2.41) | 0.36 |
GSTT1 | ||||||||||||
Salvage gene/heterozygous | 12 (60) | 22 (78.6) | 1 (–) | 1 (–) | 11 (64.7) | 19 (79.2) | 1 (–) | 1 (–) | ||||
Homozygous | 8 (40) | 6 (21.4) | 2.44 (0.69–9.09) | 0.17 | 5.19 (0.9–47.52) | 0.09 | 6 (35.3) | 5 (20.8) | 2.07 (0.51–8.8) | 0.31 | 3.37 (0.48–36.41) | 0.25 |
XRCC1 rs25487 | ||||||||||||
GG | 16 (51.6) | 16 (34.8) | 1 (–) | 1 (–) | 15 (55.6) | 14 (35.9) | 1 (–) | 1 (–) | ||||
AG | 12 (38.7) | 20 (43.5) | 0.6 (0.22–1.62) | 0.31 | 0.62 (0.21–1.84) | 0.39 | 10 (37) | 18 (46.2) | 0.75 (0.44–1.29) | 0.23 | 0.65 (0.35–1.18) | 0.23 |
AA | 3 (9.7) | 10 (21.7) | 0.3 (0.06–1.19) | 0.11 | 0.67 (0.12–3.31) | 0.63 | 2 (7.4) | 7 (17.9) | 0.56 (0.23–1.28) | 0.13 | 0.52 (0.19–1.32) | 0.54 |
ERCC1 rs11615 | ||||||||||||
CC | 6 (19.4) | 8 (17.4) | 1 (–) | 1 (–) | 5 (18.5) | 7 (17.9) | 1 (–) | 1 (–) | ||||
CT | 13 (41.9) | 24 (52.2) | 0.72 (0.21–2.61) | 0.61 | 0.89 (0.2–4.01) | 0.88 | 10 (37) | 21 (53.8) | 1.2 (0.58–2.64) | 0.56 | 1.27 (0.55–3.11) | 0.89 |
TT | 12 (38.7) | 14 (30.4) | 1.14 (0.31–4.37) | 0.84 | 1.1 (0.22–5.55) | 0.91 | 12 (44.4) | 11 (28.2) | 2.07 (0.96–4.67) | 0.56 | 2.02 (0.84–5.13) | 0.55 |
ERCC1 rs3212986 | ||||||||||||
GG | 16 (51.6) | 26 (56.5) | 1 (–) | 1 (–) | 16 (59.3) | 22 (56.4) | 1 (–) | 1 (–) | ||||
GT | 14 (45.2) | 17 (37) | 1.34 (0.52–3.46) | 0.54 | 1.24 (0.43–3.57) | 0.68 | 10 (37) | 15 (38.5) | 0.78 (0.46–1.33) | 0.87 | 0.82 (0.45–1.49) | 0.76 |
TT | 1 (3.2) | 3 (6.5) | 0.54 (0.03–4.65) | 0.61 | 1.76 (0.06–52.31) | 0.71 | 1 (3.7) | 2 (5.1) | 1.1 (0.38–2.97) | 0.77 | 1.47 (0.43–4.82) | 0.76 |
ERCC2 rs13181 | ||||||||||||
TT | 14 (45.2) | 22 (47.8) | 1 (–) | 1 (–) | 12 (44.4) | 20 (51.3) | 1 (–) | 1 (–) | ||||
GT | 17 (54.8) | 19 (41.3) | 0.71 (0.28–1.81) | 0.48 | 1.57 (0.54–4.77) | 0.41 | 15 (55.6) | 14 (35.9) | 1.12 (0.66–1.92) | 0.27 | 0.78 (0.42–1.43) | 0.33 |
GG | – | 5 (10.9) | – | – | – | 5 (12.8) | – | – | ||||
XRCC3 rs861539 | ||||||||||||
CC | 12 (38.7) | 21 (45.7) | 1 (–) | 1 (–) | 10 (37) | 18 (46.2) | 1 (–) | 1 (–) | ||||
TC | 17 (54.8) | 16 (34.8) | 1.86 (0.7–5.07) | 0.22 | 2.38 (0.78–7.7) | 0.13 | 15 (55.6) | 14 (35.9) | 1.32 (0.75–2.32) | 0.23 | 1.3 (0.7–2.44) | 0.20 |
TT | 2 (6.5) | 9 (19.6) | 0.39 (0.05–1.83) | 0.27 | 0.15 (0.01–1.13) | 0.11 | 2 (7.4) | 7 (17.9) | 1.59 (0.68–3.64) | 0.46 | 1.86 (0.71–4.82) | 0.20 |
OGG1 rs1052133 | ||||||||||||
CC | 19 (61.3) | 29 (63) | 1 (–) | 1 (–) | 16 (59.3) | 24 (61.5) | 1 (–) | 1 (–) | ||||
CG | 11 (35.5) | 15 (32.6) | 1.12 (0.42–2.95) | 0.82 | 1.58 (0.53–4.86) | 0.41 | 11 (40.7) | 14 (35.9) | 1.12 (0.65–1.93) | 0.75 | 1.35 (0.74–2.47) | 0.31 |
GG | 1 (3.2) | 2 (4.3) | 0.76 (0.03–8.51) | 0.83 | 0.96 (0.04–13.15) | 0.98 | – | 1 (2.6) | – | – | ||
Alpha-1-antytripsin | ||||||||||||
MM | 25 (83.3) | 27 (58.7) | 1 (–) | 1 (–) | 22 (84.6) | 24 (61.5) | 1 (–) | 1 (–) | ||||
MS | 4 (13.3) | 16 (34.8) | 0.27 (0.07–0.85) | 0.04 | 0.15 (0.02–0.66) | 0.02 | 3 (11.5) | 12 (30.8) | 0.73 (0.37–1.37) | 0.07 | 0.61 (0.28–1.26) | 0.08 |
MZ | 1 (3.3) | – | – | – | 1 (3.8) | – | – | – | ||||
SZ | – | 1 (2.2) | – | – | – | 1 (2.6) | – | – | ||||
SS | – | 2 (4.3) | – | – | – | 2 (5.1) | – | – | ||||
